Skip to main content
    V

    Viemed Healthcare Inc (VMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $9.15
    -0.02 (-0.22%)

    Market Cap: $347.48M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Viemed Healthcare Inc (VMD) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Viemed Healthcare (VMD) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Viemed Healthcare reported EPS of $0.11, below the $0.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(11/33)
    Avg Surprise
    +9.14%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.16
    Range$0.15 - $0.18
    4 analysts
    Revenue Consensus
    $84.56M
    Range$81.83M - $88.31M
    4 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.09
    Range$0.07 - $0.12
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.11-15.2%
    60d ago$0.10-3.5%
    30d ago$0.10-3.5%
    7d ago$0.10-3.5%
    Current$0.09
    Revenue Consensus
    $82.64M
    Range$81.83M - $83.60M
    3 analysts

    Next Report

    VMD has an expected report date of Mar 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% above the $0.14 reported for the quarter ended Dec 31, 2025.

    VMD Earnings Call

    The latest VMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 33 quarters below that had an estimate, VMD beat 11, missed 16 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $80.67M, up 12.2% from $71.91M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.11$0.12$0.11 - $0.13-8.33%Miss+22.2%30 up, 0 downNov 4, 2026$80.67M
    Jun 30, 2026$0.07$0.10$0.10 - $0.10-30.00%Miss-12.5%11 up, 1 downAug 3, 2026$78.10M
    Mar 31, 2026$0.06$0.09$0.09 - $0.09-33.33%Miss0.0%20 up, 0 downMay 5, 2026$75.41M
    Dec 31, 2025$0.14$0.13$0.12 - $0.13+7.69%Beat+34.5%21 up, 0 downMar 4, 2026$76.18M
    Sep 30, 2025$0.09$0.09$0.09 - $0.100.00%In line-10.0%20 up, 1 downNov 5, 2025$71.91M
    Jun 30, 2025$0.08$0.09N/A-11.11%Miss0.0%N/A0 up, 0 downAug 6, 2025$63.06M
    Mar 31, 2025$0.06$0.06N/A0.00%In line+50.0%N/A0 up, 0 downMay 7, 2025$59.13M
    Dec 31, 2024$0.10$0.10$0.10 - $0.10+4.10%Beat+15.7%10 up, 1 downMar 10, 2025$60.70M
    Sep 30, 2024$0.10$0.06$0.06 - $0.09+66.67%Beat+25.0%20 up, 0 downNov 6, 2024$58.00M
    Jun 30, 2024$0.08$0.07$0.07 - $0.07+14.29%Beat+33.3%10 up, 0 downAug 7, 2024$54.97M
    Mar 31, 2024$0.04$0.07$0.07 - $0.07-42.86%Miss0.0%10 up, 0 downMay 6, 2024$50.59M
    Dec 31, 2023$0.09$0.10$0.10 - $0.10-10.00%Miss+50.0%10 up, 0 downMar 6, 2024$50.74M
    Sep 30, 2023$0.08$0.09$0.08 - $0.09-11.11%Miss+166.7%20 up, 0 downNov 1, 2023$49.40M
    Jun 30, 2023$0.06$0.04$0.04 - $0.06+50.00%Beat+200.0%20 up, 0 downAug 9, 2023$43.31M
    Mar 31, 2023$0.04$0.04N/A0.00%In line0.0%10 up, 0 downMay 8, 2023$39.56M
    Dec 31, 2022$0.06$0.04N/A+50.00%Beat-40.0%10 up, 0 downMar 2, 2023$37.51M
    Sep 30, 2022$0.03$0.04$0.04 - $0.05-25.00%Miss-25.0%20 up, 0 downNov 1, 2022$35.76M
    Jun 30, 2022$0.02$0.05N/A-60.00%Miss-50.0%10 up, 0 downAug 2, 2022$33.31M
    Mar 31, 2022$0.04$0.06N/A-33.33%Miss0.0%10 up, 0 downMay 3, 2022$32.26M
    Dec 31, 2021$0.10$0.06N/A+66.67%Beat-16.7%N/AN/AMar 7, 2022$31.96M
    Sep 30, 2021$0.04$0.04N/A0.00%In line-42.9%N/AN/ANov 1, 2021$29.29M
    Jun 30, 2021$0.04$0.03N/A+33.33%Beat-91.7%N/AN/AAug 2, 2021$27.40M
    Mar 31, 2021$0.04$0.05N/A-20.00%Miss-63.6%N/AN/AMay 3, 2021$28.42M
    Dec 31, 2020$0.12$0.03N/A+300.00%Beat+100.0%N/AN/AMar 3, 2021$31.20M
    Sep 30, 2020$0.07$0.09N/A-22.22%Miss0.0%N/AN/ANov 4, 2020$33.45M
    Jun 30, 2020$0.48$0.26N/A+84.62%Beat+860.0%N/AN/AAug 5, 2020$42.85M
    Mar 31, 2020$0.11$0.08N/A+37.50%Beat+120.0%N/AN/AMay 4, 2020$23.81M
    Dec 31, 2019$0.06$0.07N/A-14.29%Miss+20.0%N/AN/AMar 3, 2020$21.45M
    Sep 30, 2019$0.07$0.07N/A0.00%In line+16.7%N/AN/ANov 4, 2019$20.37M
    Jun 30, 2019$0.05$0.06N/A-16.67%Miss-16.7%N/AN/AAug 9, 2019$20.32M
    Mar 31, 2019$0.05$0.08N/A-37.50%Miss-16.7%N/AN/AMay 6, 2019$18.11M
    Dec 31, 2018$0.05$0.08N/A-37.50%MissN/AN/AN/AFeb 27, 2019$18.49M
    Sep 30, 2018$0.06$0.06N/A0.00%In lineN/AN/AN/ANov 5, 2018$17.16M
    Jun 30, 2018$0.06N/AN/AN/AN/AN/AN/AN/AAug 13, 2018$15.51M
    Mar 31, 2018$0.06N/AN/AN/AN/AN/AN/AN/AMay 7, 2018$14.11M
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.37, up 14.2% from the year before. It was $0.23 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.37+14.2%
    Dec 31, 2024$0.32+20.0%
    Dec 31, 2023$0.27+80.0%
    Dec 31, 2022$0.15-31.8%
    Dec 31, 2021$0.22-71.8%
    Dec 31, 2020$0.78+239.1%
    Dec 31, 2019$0.23N/A
    Dec 31, 2018$0.23N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,0408
    2026Q2Jun 30, 20263,8316
    2026Q1Mar 31, 20264,4555
    2025Q4Dec 31, 20254,5867
    2025Q3Sep 30, 20254,4287
    2025Q2Jun 30, 20253,5306
    2025Q1Mar 31, 20254,9437
    2024Q4Dec 31, 20245,0936

    2026Q3 Earnings Call

    Opening remarks

    Trae Paul Fitzgerald CFO Thank you, and good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. Federal Securities Laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. Forward-looking statements made in this conference call are made as of today, and the company undertakes no obligations to update or revise any forward-looking statements except as required by law. The third-quarter financial supplement and financial news release, as well as the related financial statements, are available on the SEC's website. With that, I will turn the call over to our Chief Executive Officer, Casey Hoyt.

    Casey Hoyt CEO Thank you, Trae. Good morning, everyone, and thank you for joining us. Before getting into the results, I want to thank our roughly 1,500 employees. Their daily work with patients and referral partners is what makes our growth possible. I appreciate the care they provide and the work they put into serving more patients as Viemed continues to grow. The third quarter was another strong quarter for Viemed, with record revenue of $80.7 million, representing 12.2% growth over last year. Just as importantly, that growth translated into stronger earnings. Net income attributable to Viemed increased 32% year over year and approximately 68% from the second quarter. We are continuing to grow the business at a double-digit pace, demonstrating the earnings potential of the platform we have built. For the first time since the Lehan acquisition, both the current- and prior-year quarters include a full three months of Lehan's operations. That gives us a much clearer picture of our growth, with a 12.2% increase reflecting expansion across our existing businesses rather than the incremental revenue contribution of an acquisition. Sleep therapy was a particular source of strength this quarter, and we are also seeing encouraging results from bringing maternal health services into our established Viemed markets. The success of those initial maternal health markets gives us confidence to broaden the rollout. We are now on track to enter two additional states per quarter beginning in the fourth quarter, establishing a regular pace of expansion. The markets we have already entered are still early in their development.

    Frequently Asked Questions About VMD

    When is Viemed Healthcare's next earnings date?

    Viemed Healthcare's next earnings report is expected for Mar 2, 2027.

    Did VMD beat earnings estimates last quarter?

    No. Viemed Healthcare reported EPS of $0.11 for the quarter ended Sep 30, 2026, below the $0.12 estimate by 8.33%.

    What EPS do analysts expect from VMD next quarter?

    The consensus EPS estimate for Viemed Healthcare for the quarter ending Dec 31, 2026 is $0.16 from 4 analysts, with estimates from $0.15 to $0.18.

    How often does VMD beat earnings estimates?

    Viemed Healthcare beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.87%.